2.4.0.84071 - Disclosure - Commitments, Collaborations and Contingencies (Details 2)truefalsefalse1false USDfalsefalse$D2012http://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$D2011http://www.sec.gov/CIK0001436304duration2011-01-01T00:00:002011-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D2010http://www.sec.gov/CIK0001436304duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDtruefalse$D2012Q2_M0531_LicenseAgreementMember_BayerMemberhttp://www.sec.gov/CIK0001436304duration2012-05-30T00:00:002012-05-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseBayerus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_BayerMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.kytherabiopharma.com/20121231itemkyth0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$D2010Q3_M08_BayerMember_LicenseAgreementMemberhttp://www.sec.gov/CIK0001436304duration2010-08-01T00:00:002010-08-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseBayerus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_BayerMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$D2012_LicenseAgreementMember_BayerMemberhttp://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseBayerus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_BayerMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.kytherabiopharma.com/20121231itemkyth0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$D2011_LicenseAgreementMember_BayerMemberhttp://www.sec.gov/CIK0001436304duration2011-01-01T00:00:002011-12-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseBayerus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_BayerMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$D2010_LicenseAgreementMember_BayerMemberhttp://www.sec.gov/CIK0001436304duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseBayerus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_BayerMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalseD2012Q2_M0531_LicenseAgreementMember_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberhttp://www.sec.gov/CIK0001436304duration2012-05-30T00:00:002012-05-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseLA Biomedus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$10false USDtruefalse$D2005Q3_M08_LicenseAgreementMember_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberhttp://www.sec.gov/CIK0001436304duration2005-08-01T00:00:002005-08-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseLA Biomedus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false truefalseD2012_LicenseAgreementMember_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberhttp://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseLA Biomedus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMember12false USDtruefalse$D2010_LicenseAgreementMember_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberhttp://www.sec.gov/CIK0001436304duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseLA Biomedus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13false USDtruefalse$I2010Q3_M0831_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMember_LicenseAgreementMemberhttp://www.sec.gov/CIK0001436304instant2010-08-31T00:00:000001-01-01T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseLA Biomedus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LosAngelesBiomedicalResearchInstituteAtHarborUCLAMedicalCenterMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14false truefalseD2012_SupplyArrangementsMember_PfizerIncMemberhttp://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00falsefalseSupply Arrangementsus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_SupplyArrangementsMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalsePfizerus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_PfizerIncMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMember15false truefalseD2012_SupplyArrangementsMember_HospiraIncMemberhttp://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00falsefalseSupply Arrangementsus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_SupplyArrangementsMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseHospiraus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_HospiraIncMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMember16false truefalseD2012_SupplyArrangementsMember_HospiraIncMember_MinimumMemberhttp://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00falsefalseSupply Arrangementsus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_SupplyArrangementsMemberus-gaap_TypeOfArrangementAxisexplicitMemberfalsefalseHospiraus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldikyth_HospiraIncMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli01true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaboration Arrangements2false 4us-gaap_IncreaseDecreaseInDeferredRevenueus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-3847000-3847000USD$falsetruefalse2truefalsefalse-12984000-12984000USD$falsetruefalse3truefalsefalse1683100016831000USD$falsetruefalse4falsefalsefalse00falsefalsefalse5truefalsefalse2131900021319000USD$falsetruefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Upfront license fee paid3false 4us-gaap_GainContingencyUnrecordedAmountus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse297000000297000000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 17 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355 false2Contingent income4false 4us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognizedus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1580000015800000falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of consideration recognized during the period for the milestone or milestones.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 false2Contingent income received5false 4kyth_NumberOfConsecutiveValidatedManufacturingLotskyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse22falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of consecutive validated manufacturing lots.No definition available.false256Number of consecutive validated manufacturing lots6false 4us-gaap_DeferredRevenueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse2131900021319000falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A false2Deferred revenue7false 4us-gaap_RestrictedCashAndCashEquivalentsus-gaap_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:monetaryItemTypemonetaryThe carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Audit and Accounting Guide (AAG) -Number AAG-BRD -Paragraph 80 -Subparagraph Exhibit 4-8, 3 -IssueDate 2006-05-01 -Chapter 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false2Restricted cash8false 4kyth_DeferredDevelopmentFundsReceivedkyth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1740000017400000falsefalsefalse5truefalsefalse2224700022247000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents amount deferred development fund during the period.No definition available.false2Deferred development funds9false 4kyth_PeriodOfAdvanceNoticeWhichIsRequiredToTerminateAgreementkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00180 daysfalsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse0090 daysfalsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse0024 monthsfalsefalsefalse15falsefalsefalse0024 monthsfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of advance notice which is required to terminate the agreement.No definition available.false0Period of advance notice which is required to terminate the agreement10false 4kyth_ExpirationPeriodOfRoyaltiesFromDateOfFirstCommercialSaleOfRelatedProductkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse0015 yearsfalsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of expiration of royalties from the date of first commercial sale of related product.No definition available.false0Expiration period of royalties from the date of first commercial sale of related product11false 4kyth_NumberOfTerritoriesIntoWhichEntryByQualifyingCompetitiveProductDoesNotResultInReductionInRoyaltyPaymentskyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse11falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of territories into which entry by qualifying competitive product does not result in reduction in royalty payments.No definition available.false256Number of territories into which entry by qualifying competitive product does not result in reduction in royalty payments12false 4kyth_AmountsRecognizedToOffsetResearchAndDevelopmentExpensekyth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse1007500010075000falsefalsefalse7truefalsefalse1461500014615000falsefalsefalse8truefalsefalse10390001039000falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the amounts recognized to offset research and development expense by the entity during the period.No definition available.false2Amounts recognized as offsets to research and development expense13false 4kyth_MilestonePaymentkyth_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse500000500000falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the milestone payment made to acquire assets.No definition available.false2Milestone payment14false 4kyth_NonRoyaltySublicenseFeeEqualToCertainPercentageOfSublicenseIncomekyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10truetruefalse0.100.10falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the non-royalty sublicense fees equal to a certain percentage of sublicense income.No definition available.false0Non-royalty sublicense fees equal to a certain percentage of sublicense income (as a percent)15false 4kyth_MaximumNonRoyaltySublicenseFeeskyth_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse50000005000000falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the maximum non-royalty sublicense fees, which can be paid by the entity under the collaborative and licensing agreement.No definition available.false2Maximum non-royalty sublicense fees16false 4kyth_RightToIssueCapitalAgainstPaymentOfSublicenseFeesInPercentkyth_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10truetruefalse0.500.50falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the right held by the entity to satisfy payment of sublicense fees against issuance of capital, expressed as a percentage.No definition available.false0Right to issue capital to satisfy payment of sublicense fees (as a percent)17false 4us-gaap_DeferredCostsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse15800001580000falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse19500001950000falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 false2Non-royalty sublicense fee expenses18false 4kyth_NonRoyaltySublicenseFeePaidkyth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12truefalsefalse390000390000falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the non-royalty sublicense fee paid in cash by the entity during the period.No definition available.false2Non-royalty sublicense fee paid19false 4kyth_DeferredNonRoyaltySublicenseFeekyth_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12truefalsefalse15600001560000USD$falsetruefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the remainder of the non-royalty sublicense fee, as on balance sheet date.No definition available.false2Remainder of non-royalty sublicense fee20false 4kyth_DeferredNonRoyaltySublicenseFeePercentagePaidInCashkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9truetruefalse0.500.50falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the percentage of remainder of the non-royalty sublicense fee, which is paid in cash.No definition available.false0Non-royalty sublicense fee paid in cash upon initial public offering (as a percent)21false 4kyth_DeferredNonRoyaltySublicenseFeePercentagePaidInStockkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9truetruefalse0.500.50falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the percentage of remainder of the non-royalty sublicense fee, which is paid in stock.No definition available.false0Non-royalty sublicense fee paid in stock upon initial public offering (as a percent)22false 4kyth_PeriodOfWrittenNoticeOfUncuredMaterialBreachWhichIsRequiredToTerminateAgreementkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse0060 daysfalsefalsefalse15falsefalsefalse0060 daysfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of written notice of uncured material breach, which is required to terminate the agreement.No definition available.false0Period of written notice of uncured material breach, which is required to terminate the agreement23false 4kyth_PeriodFromReceivingInvoiceAfterWhichPaymentAreDueToVendorkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse0030 daysfalsefalsefalse15falsefalsefalse0030 daysfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period after receiving invoice during which payments are due to vendor.No definition available.false0Period after receiving invoice during which payments are due to vendor24false 4kyth_TermOfAgreementkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse005 yearsfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the term of the agreement executed by the entity.No definition available.false0Term of agreement25false 4kyth_AdditionalAndSuccessivePeriodOfExtensionToInitialTermOfAgreementkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse002 yearsfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the additional and successive period of extension to initial term of agreement executed by the entity.No definition available.false0Additional and successive period of extension to initial term of agreement26false 4kyth_PeriodOfNonPerformanceDueToForceMajeureAfterWhichNoticeCanBeGivenToTerminateAgreementkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00180 daysfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of non-performance by other party due to force majeure after which the notice can be given to terminate the agreement.No definition available.false0Period of non-performance by other party due to force majeure after which notice can be given to terminate agreement27false 4kyth_PeriodOfRightToBeSoleSupplierOfDrugProductToEntityFollowingCommercializationkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse003 yearsfalsefalsefalse16falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period following the commercialization during which the vendor has the right to be sole supplier of the entity's drug product.No definition available.false0Period following the commercialization during which the vendor has the right to be sole supplier of drug product28false 4kyth_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProductkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16truetruefalse0.750.75falsefalsefalsenum:percentItemTypepureRepresents the right of supply of drug product as a percentage of its annual requirement to the entity.No definition available.false0Right of supply as a percentage of annual requirement of drug productfalseCommitments, Collaborations and Contingencies (Details 2) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.kytherabiopharma.com/role/DisclosureCommitmentsCollaborationsAndContingenciesDetails21628